PTC299 IS A NOVEL DHODH INHIBITOR FOR USE IN TREATMENT OF AML
EHA Learning Center, Marla Weetall, 266621
WHOLE-TRANSCRIPTOME SEQUENCING OF CYTOGENETICALLY NORMAL PEDIATRIC ACUTE MYELOID LEUKEMIA
EHA Learning Center, Lilit Ghukasyan, 266622
SNP ARRAY REVEALS A NEW DELETION OF JAK2 IN AML PATIENTS
EHA Learning Center, Claudio CERCHIONE, 266637
GOOD SENSITIVITY OF ACUTE MYELOID LEUKEMIAS INVOLVING ONLY GRANULOCYTE-MONOCYTE LINE (GM-AML) TO STANDARD-DOSE INDUCTION THERAPY (SICT) IS NOT INFLUENCED BY AGE
EHA Learning Center, Petr Lemez, 266638
UPDATED RESULTS FROM A PHASE 1 STUDY OF GILTERITINIB IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED AML
EHA Learning Center, Keith Pratz, 266653
FINAL REPORT: CLINICAL STUDY OF ORAL ARSENIC TRIOXIDE CAPSULE FORMULATION, ORH-2014, DEMONSTRATING HIGH BIOAVAILABILITY, GOOD SAFETY AND TOLERABILITY IN PATIENTS WITH ADVANCED HEMATOLOGIC DISORDERS
EHA Learning Center, Farhad Ravandi, 266654
AGE >70 YEARS, HIGH-RISK CYTOGENETICS, SORROR COMORBIDITY SCORE >1 AND BLAST COUNT>40% IN BM ARE RISK FACTORS FOR INDUCTION FAILURE OF STANDARD CHEMOTHERAPY WITH ANTHRACYCLINE AND CYTARABINE IN AML
EHA Learning Center, Ahmet ELMAAGACLI, 266669
IMPACT OF CYTOMEGALOVIRUS REACTIVATION ON RELAPSE RATE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIA
EHA Learning Center, Nour ben abdeljelil, 266670
SAFETY ANALYSIS OF AUSTRALASIAN LEUKAEMIA & LYMPHOMA GROUP NHL29: A PHASE II STUDY OF IBRUTINIB, RITUXIMAB AND MINI-CHOP IN VERY ELDERLY PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B CELL LYMPHOMA
EHA Learning Center, Emma Verner, 266685
THE ECHELON-2 TRIAL: RESULTS OF A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF BRENTUXIMAB VEDOTIN AND CHP (A+CHP) VERSUS CHOP IN FRONTLINE TREATMENT OF PATIENTS WITH CD30+ PERIPHERAL T-CELL LYMPHOMAS
EHA Learning Center, Tim Illidge, 266687
ORAL CHOP LIKE CHEMOTHERAPY IN ELDERLY PATIENTS WITH HIGH-GRADE NON HODGKIN B CELL LYMPHOMA
EHA Learning Center, Stéphanie Guidez, 266702
THE INCIDENCE AND CLINICAL IMPACT OF RHOA G17V MUTATION IN ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA PATIENTS
EHA Learning Center, Ya-Ting Hsu, 266703
HEMOPHILIA ASSOCIATED BONE PATHOLOGY IMPACTS QUALITY OF LIFE
EHA Learning Center, Galen Goldscheitter, 266719
NOVEL COMPOUND HETEROZYGOUS MUTATIONS CAUSING FACTOR XI DEFICIENCY IN UNRELATED TWO CHINESE PATIENTS
EHA Learning Center, Qian Li, 266720
IRON MOBILIZATION IN A REAL LIFE COHORT OF APLASTIC ANEMIA PATIENTS TREATED WITH ELTROMBOPAG
EHA Learning Center, Francesca CAVALLARO, 266737
ABSENCE OF GPI-NEGATIVE CELLS AT DIAGNOSIS AND LOW NEUTROPHIL COUNT 2 MONTHS AFTER ATGAM BASED TREATMENT ARE ASSOCIATED WITH LOWER 6-MONTH RESPONSE RATE IN ADULTS WITH (VERY) SEVERE APLASTIC ANEMIA
EHA Learning Center, Jennifer Tjon, 266738
MONOCYTIC BUT NOT GRANULOCYTIC MDSCS INCREASE WITH IBRUTINIB BUT NOT ACALABRUTINIB TREATMENT IN EM-TCL1 MICE WITH CLL, SUGGESTING A ROLE FOR ITK INHIBITION IN MONOCYTIC MDSCS
EHA Learning Center, Arantxa Romero-Toledo, 266752
THE PI3KD-SELECTIVE INHIBITOR IDELALISIB INDUCES T AND NK CELL DYSFUNCTION INDEPENDENT OF B-CELL MALIGNANCY-ASSOCIATED IMMUNOSUPPRESION
EHA Learning Center, Lisa Rohrbacher, 266753
COMPLEX STRUCTURAL VARIANTS LEAD TO GENE INACTIVATION RATHER THAN EXPRESSION OF DE NOVO FUSION GENES IN CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Karla Plevova, 266754
PHASE 2 STUDY OF ACALABRUTINIB IN IBRUTINIB-INTOLERANT PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Kerry Rogers, 266768
THE USE OF THE BCL-2 INHIBITOR IN CLL PATIENTS WHO PROGRESSED AFTER B-CELL-RECEPTOR INHIBITORS: A RETROSPECTIVE MULTICENTER ITALIAN EXPERIENCE
EHA Learning Center, Luca Laurenti, 266769
IMPACT OF COMORBIDITIES ON OUTCOMES OF THERAPY WITH IDELALISIB (IDELA), A PHOSPHOINOTISIDE-3 KINASE-DELTA INHIBITOR, IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
EHA Learning Center, Max Gordon, 266770
INDIVIDUAL RESPONSE OF CML PATIENTS TO TKI DOSE REDUCTION CAN RELIABLY IDENTIFY PATIENTS WITH HIGH RISK OF MOLECULAR RELAPSE AFTER TREATMENT CESSATION
EHA Learning Center, Andrea Gottschalk, 266784
CHROMATIN TOPOLOGY AND THREE-DIMENSIONAL ORGANIZATION OF CHROMOSOME TERRITORIES 9 AND 22 IN CD34+ BONE MARROW CELLS FROM CHRONIC MYELOID LEUKEMIA PATIENTS.
EHA Learning Center, Eunice Fabian-Morales, 266785
CYTOKINE AND ARGINASE-1 EXPRESSION DYNAMICS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA REVEALS EARLY MOLECULAR RESPONSE TO IMATINIB
EHA Learning Center, Irene Larripa, 266786
THE POTENTIAL IMPACT OF SWITCH TO SECOND GENERATION TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA PATIENTS IN CHRONIC PHASE WHO HAD NO OPTIMAL RESPONSE TO 3 MONTHS OF INITIAL IMATINIB THERAPY
EHA Learning Center, Maria Pankrashkina, 266800
ANALYSIS OF BCR-ABL1 TRANSCRIPT LEVELS AT 3 MONTHS IN PREDICTING OVERALL RESPONSE IN PATIENTS OF CHRONIC MYELOID LEUKEMIA- CHRONIC PHASE ON 1ST LINE THERAPY WITH IMATINIB MESYLATE
EHA Learning Center, Asif Iqbal, 266801
FACTORS INFLUENCING PATIENT PREFERENCES FOR DISCONTINUATION OF TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA.
EHA Learning Center, Bogdan Ochrem, 266802
SCREENING FOR HEREDITARY SPHEROCYTOSIS IN DAILY PRACTICE: WHICH IS THE BEST ALGORITHM USING ERYTHROCYTE AND RETICULOCYTE PARAMETERS?
EHA Learning Center, Anne-Sophie Adam, 266816
IDENTIFICATION OF MUTATIONS IN RED CELL MEMBRANOPATHIES USING NGS-TARGETED SEQUENCING PANEL
EHA Learning Center, Tejashree More, 266817
: MOLECULAR STUDY OF RED CELL NADH-CYTOCHROME B5 REDUCTASE DEFICIENCY IN 21 INDIAN PATIENTS WITH RECESSIVE HEREDITARY METHEMOGLOBINAEMIA
EHA Learning Center, Prabhakar Kedar, 266818
SAFETY AND TOLERABILITY OF ALLOGENEIC, OFF-THE SHELF PLACENTAL NATURAL KILLER CELLS (PNK 007) IN PHASE 1 MULTIPLE MYELOMA AND ACUTE MYELOID LEUKEMIA STUDIES (NCT02955550 AND NCT02781467)
EHA Learning Center, Sharmila Koppisetti, 266832
CAR T-CELL THERAPY FOR LYMPHOMAS IN ITALY: THE ISTITUTO NAZIONALE DEI TUMORI OBSERVATIONAL STUDY AFTER THE EMA APPROVAL
EHA Learning Center, Giulia Perrone, 266833
INTRA-BONE DLI AT RELAPSE AFTER ALLO-HSCT IMPROVES SURVIVAL WITH LOWERING OF PD-1 POSITIVITY OF CD8+ CELLS AND PRESERVATION OF THE PROFILE OF TCR BETA DOMINANT CLONES IN THE MARROW
EHA Learning Center, Andrzej Lange, 266834
RAPID MAST CELL GENERATION FROM GATA2 REPORTER HUMAN PLURIPOTENT STEM CELLS
EHA Learning Center, Carmen Rodriguez Seoane, 266849
HES1 AND HES4 HAVE SIMILAR AND DIVERSE CAPACITIES TO MEDIATE HUMAN NOTCH-DEPENDENT HEMATOPOIETIC LINEAGE DECISIONS.
EHA Learning Center, Matthias De Decker, 266850
APPLICATION OF FLOW SOM TO CLASSICAL FLOW CYTOMETRY : UNSUPERVISED ANALYSIS OF HEMATOPOIESIS AND HEMATOLOGICAL MALIGNANCIES.
EHA Learning Center, Marie Christine BÉNÉ, 266851
EXTRANODAL AND SPLEEN DISEASE DETECTED BY FDG-PET/CT IS ASSOCIATED WITH EARLY CLINICAL FAILURE IN UNTREATED FOLLICULAR LYMPHOMA
EHA Learning Center, Frederique St-Pierre, 266866
PRIMARY THERAPY AND SURVIVAL OF FOLLICULAR LYMPHOMA IN THE NETHERLANDS: A POPULATION-BASED ANALYSIS AMONG 12,008 PATIENTS DIAGNOSED FROM 1989 TO 2016
EHA Learning Center, Manette Dinnessen, 266867
CLINICO-BIOLOGICAL CHARACTERISTICS AND TREATMENT OUTCOMES FOR BLASTOID MANTLE CELL LYMPHOMA PATIENTS INCLUDED IN CLINICAL TRIALS. A LYSA STUDY.
EHA Learning Center, Mathieu BALDACINI, 266868
IMPROVEMENTS IN OUTCOME OF MANTLE-CELL LYMPHOMA (MCL) ARE MOSTLY DUE TO ADVANCES IN INDUCTION THERAPY AND AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT) - A REAL-LIFE NON-INTERVENTIONAL STUDY OF KROHEM
EHA Learning Center, Igor Aurer, 266882
CLINICAL ASPECTS, MORPHOLOGICAL ANALYSIS AND IMMUNOHISTOCHEMICAL CHARACTERISTICS OF PATIENTS WITH FOLLICULAR LYMPHOMA IN DUODENUM BIOPSY: CASES WITH RESTRICT DISEASE VERSUS ADVANCED PRESENTATION.
EHA Learning Center, Guilherme Duffles, 266883
ISAVUCONAZOLE IN HEMATOLOGICAL PATIENTS: FINAL RESULTS OF A REAL-LIFE MULTICENTER SEIFEM (SORVEGLIANZA EPIDEMIOLOGICA DELLE INFEZIONI NELLE EMOPATIE) STUDY
EHA Learning Center, Chiara Cattaneo, 266884
EFFICACY OF ACTIVE SURVEILLANCE IN REDUCING MORTALITY DUE TO MULTIDRUG RESISTANT BACTERIA IN ACUTE LEUKEMIA
EHA Learning Center, Christelle Castañón, 266898
INFECTIOUS COMPLICATIONS OF NIVOLUMAB THERAPY IN RELAPSED/REFRACTORY HODGKIN’S LYMPHOMA
EHA Learning Center, Yuliya Rogacheva, 266899
CLINICAL IMPLICATIONS OF AZOLE-RESISTANT VERSUS AZOLE-SUSCEPTIBLE INVASIVE ASPERGILLOSIS IN HEMATOLOGICAL MALIGNANCY (CLARITY) - A MULTICENTER STUDY
EHA Learning Center, Danila Seidel, 266900
EFFICACY AND SAFETY OF INTRAVENOUS IRON THERAPY IN CHILDREN: A KOREAN SINGLE CENTER STUDY
EHA Learning Center, Nani Jung, 266914
TISSUE IRON DISTRIBUTION IN PATIENTS WITH LOW-RISK MDS
EHA Learning Center, Regine Grosse, 266915
SOLUBLE TRANSFERRIN RECEPTOR AND ITS FERRITIN INDEX IN COMPARISON WITH BIOCHEMICAL AND HEMATOLOGICAL PARAMETERS FOR THE DIFFERENTIATION OF ANEMIA STATES AND CORRELATION WITH IV IRON RESPONSE
EHA Learning Center, Nina Petkova, 266916
FEASIBILITY AND PRELIMINARY RESULTS OF A PROSPECTIVE EVALUATION OF RESIDUAL DISEASE IN DIFFUSE LARGE B-CELL LYMPHOMAS USING DEEP SEQUENCING OF CELL FREE DNA AND DNA FROM FORMALIN FIXED BIOPSIES
EHA Learning Center, Cristiana Carniti, 266930
ISOLATION AND VALIDATION OF THE FIRST FUNCTIONAL HLA-A*01:01-RESTRICTED EBV-LMP2-SPECIFIC T-CELLS FOR TREATMENT OF EBV-ASSOCIATED TYPE II/III LYMPHOMAS
EHA Learning Center, Wesley Huisman, 266931
CHANGES IN THE SECRETOME COMPOSITION OF MULTIPOTENT MESENCHYMAL STROMAL CELLS PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA WITHOUT BONE MARROW INVOLVEMENT
EHA Learning Center, Nataliya Petinati, 266932
IN VIVO 18F-FLUORO-THYMIDINE POSITRON EMISSION TOMOGRAPHY IMAGING FOR DISEASE MONITORING IN A MOUSE MODEL OF HIGH-RISK MYELODYSPLASTIC SYNDROME
EHA Learning Center, Rose-Ann Padua, 266946
VARIABILITY IN THE EXTENT OF DEL(5Q) AND ITS CLINICAL IMPLICATION IN MYELODYSPLASTIC SYNDROMES (MDS).
EHA Learning Center, Zuzana Zemanova, 266947
MYELOMONOCYTIC SKEWING IN CHRONIC MYELOMONOCYTIC LEUKEMIA: PHENOTYPIC, GENOTYPIC AND BIOLOGIC FEATURES AND IMPACT ON SURVIVAL
EHA Learning Center, Klaus Geissler, 266948
CIRCULATING TUMOR DNA AS A LIQUID BIOPSY IN SMOLDERING MULTIPLE MYELOMA TO IDENTIFY BIOMARKERS OF PROGRESSION
EHA Learning Center, Martina Manzoni, 266962
CLONAL EVOLUTION IN MULTIPLE MYELOMA PATIENTS RECEIVING MAINTENANCE THERAPY
EHA Learning Center, Carolina Terragna, 266963
PHF19 INDUCES EZH2 PHOSPHORYLATION AND PROMOTES DRUG RESISTANCE IN MULTIPLE MYELOMA
EHA Learning Center, Chen-Xing Du, 266964
TRYPTOPHAN DEPRIVATION DUE TO INCREASED IDO-1 TRIGGERS A METABOLIC ADAPTIVE RESPONSE AND DOWN-REGULATES CD38 IN MULTIPLE MYELOMA
EHA Learning Center, Alessandra Romano, 266979
TARGETING MITOCHONDRIAL FITNESS OF MYELOMA CELLS WITH TAK-242 OVERCOMES BORTEZOMIB RESISTANCE
EHA Learning Center, Cesarina Giallongo, 266980
EXOSOMAL CARGO IN MONOCLONAL GAMMOPATHIES COMPARED TO HEALTHY DONORS AND ITS POTENTIAL RELATION TO MYELOMA AGGRESSIVENESS.
EHA Learning Center, Bruna Ferreira, 266981
AN EARLY, WITHIN THE FIRST MONTH, AND DEEP RESPONSE, SHOULD BE THE GOAL OF THERAPY IN AL AMYLOIDOSIS
EHA Learning Center, Efstathios Kastritis, 266995
SAFETY AND EFFICACY OF ONCE-WEEKLY CARFILZOMIB DOSING IN FRAIL PATIENTS: A SUBGROUP ANALYSIS FROM THE PHASE 3 A.R.R.O.W. STUDY
EHA Learning Center, María-Victoria Mateos, 266996
PEPTIDE VACCINATION AGAINST PD-L1 (IO103) IN MULTIPLE MYELOMA - A PHASE I FIRST IN HUMAN TRIAL
EHA Learning Center, Nicolai Grønne JØRGENSEN, 266997
FLOW-MEDIATED DILATATION AND AORTIC BLOOD PRESSURE PREDICT CARDIOVASCULAR ADVERSE EVENTS DURING CARFILZOMIB TREATMENT: A PROSPECTIVE STUDY IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA.
EHA Learning Center, Efstathios Kastritis, 267011
COMPARATIVE EFFECTIVENESS OF FRONT-LINE TREATMENTS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE TRANSPLANT INELIGIBLE
EHA Learning Center, Thierry Facon, 267012
DARATUMUMAB IS WELL TOLERATED AND INDUCES A RAPID HEMATOLOGICAL RESPONSE IN NON IG-M LIGHT CHAIN AMYLOIDOSIS WITH SEVERE CARDIAC IMPAIRMENT.
EHA Learning Center, Romain Gounot, 267027
CHARACTERISTICS AND TREATMENT OUTCOMES OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) NON-STEM CELL TRANSPLANT (NSCT) PATIENTS IN THE UK, GERMANY, AND FRANCE
EHA Learning Center, Dorothy Romanus, 267028
IMMUNE CHECKPOINT (PD-1, PD-L1, PD-L2, AND CTLA-4) EXPRESSION IN PLASMA CELL MYELOMA
EHA Learning Center, Min Young Lee, 267043
THE SIGNIFICANCE OF UNEXPECTED PHARMACOKINETICS OF DARATUMUMAB DURING LONG-TERM MONTHLY TREATMENT FOR MYELOMA
EHA Learning Center, Linda Little, 267044
PROTEASOME INHIBITOR CARFILZOMIB HAS SYNTHETIC LETHALITY WITH RUXOLITINIB IN MYELOPROLIFERATIVE NEOPLASMS
EHA Learning Center, Simone Claudiani, 267059
BLOCKADE OF TNFR1 RATHER THAN TNFR2 IMPROVES HEMATOCRIT AND REDUCES BLOOD PRO-INFLAMMATORY CYTOKINE LEVELS IN THE VAV1-CRE X JAK2+/V617F MPN MOUSE MODEL
EHA Learning Center, Peter Müller, 267060
FEDRATINIB IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASM (MPN)-ASSOCIATED MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX): A REANALYSIS OF THE PHASE 2 JAKARTA-2 STUDY
EHA Learning Center, Claire Harrison, 267076
LONG-TERM FOLLOW UP OF JAK INHIBITOR (JAKI) TREATED PATIENTS WITH MYELOFIBROSIS: IMPACT OF MOLECULAR ENHANCED INTEGRATED SCORING SYSTEMS AND TYPE OF JAKI THERAPY FAILURE ON SURVIVAL
EHA Learning Center, Caroline MCNAMARA, 267077
COATED PLATELET FUNCTION IS RELATED TO BLEEDING PHENOTYPE IN PATIENTS WITH INHERITED THROMBOCYTOPENIA
EHA Learning Center, Nanna Broens, 267092
APPLICATION OF WHOLE EXOME SEQUENCING FOR PATIENTS WITH INHERITED PLATELET DISORDERS
EHA Learning Center, Marian Stevens-Kroef, 267093
ASSESSING TREATMENT RESPONSE IN CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA WITH AN INNOVATIVE SHEAR FLOW-BASED ASSAY
EHA Learning Center, Chiara VENDRAMIN, 267109
NEXT-GENERATION SEQUENCING REVEALS DISTINCT EXPANDED T-CELL RECEPTOR (TCR) Β-CHAIN CLONOTYPES IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP)
EHA Learning Center, Amna Malik, 267110
QUALITY OF LIFE AND PERCEPTION OF HEALTH CARE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES IN THE UK
EHA Learning Center, Esther OLIVA, 267125
QUALITY OF LIFE IN PATIENTS WITH RRMM DURING IXA-THAL-DEX INDUCTION AND IXAZOMIB MAINTENANCE THERAPY IN COMPARISON TO THE GENERAL POPULATION
EHA Learning Center, Heinz Ludwig, 267126
WHEN IS A CT NEEDED TO DIAGNOSE ACUTE PULMONARY EMBOLISM IN INDIVIDUALS WITH SICKLE CELL DISEASE
EHA Learning Center, Nadirah El-Ahmin, 267141
ANTISICKLING EFFECTS OF 1,2,3-TRIAZOLE DERIVATIVES AS POTENTIAL NEW DRUGS FOR SICKLE CELL DISEASE
EHA Learning Center, CLEMILSON BERTO JUNIOR, 267142
MULTIPARAMETRIC PREDICTIVE SCORE FOR GRAFT VERSUS HOST DISEASE (GVHD) IN PATIENTS SUBMITTED TO ALLOGENEIC STEM CELLS TRANSPLANTATION (SCT)
EHA Learning Center, Alessandro TURRA, 267157
OUTCOMES OF AUTOLOGOUS AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR BPDCN
EHA Learning Center, Muzaffar Qazilbash, 267158
EARLY ENGRAFTMENT OF UNRELATED CORD BLOOD TRANSPLANTATION IN PATIENTS WITH ACQUIRED SEVERE APLASTIC ANEMIA USING CONDITIONING REGIMEN WITHOUT ANTI-THYMOCYTE GLOBULIN
EHA Learning Center, Xiang WAN, 267174
COMPARISON OF THE INCIDENCE AND OUTCOMES OF TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY BETWEEN HAPLOIDENTICAL AND MATCHED SIBLING DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Learning Center, Ruo-Yun Gui, 267175
HLA-DRB1*15 INCREASES THE RISK OF RED BLOOD CELLS ALLOANTIBODIES IN PATIENTS WITH BETA THALASSEMIA MAJOR
EHA Learning Center, Louza Al Mashaykhi, 267191
USE OF THE NEW DEFERASIROX FORMULATION IN PEDIATRIC THALASSEMIA PATIENTS: ONE YEAR RESULTS
EHA Learning Center, Alkistis ADRAMERINA, 267192
CENTRAL VEIN CATHETERIZATION IN ONCOHEMATOLOGICAL PRACTICE: RISK OF COMPLICATIONS
EHA Learning Center, Nikolay Romanenko, 267207
FUNCTIONAL PROPERTIES OF THE HEMOGLOBIN FROM STORED RED BLOOD CELLS CONCENTRATES AFTER LEUKOREDUCTION
EHA Learning Center, Susan Jorge, 267208
BENEFITS OF RNA SEQUENCING IN DETECTING RECURRENT AND NOVEL FUSION TRANSCRIPTS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Rabia Shahswar, 267223
ONCOGENIC COOPERATION BETWEEN TAL1 EXPRESSION AND PI3K/AKT PATHWAY ACTIVATION IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Naomi Thielemans, 267224
CAR-T CELL THERAPY BRIDGING TO ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION LED TO SUPERIOR SURVIVAL FOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS OUT OF REMISSION
EHA Learning Center, Jia CHEN, 267240
COMBINATION BCL-2 INHIBITOR THERAPY WITH VENETOCLAX AND NAVITOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOBLASTIC LYMPHOMA
EHA Learning Center, Vinod A. Pullarkat, 267241
FEASIBLE OUTCOME OF BLINATUMOMAB FOLLOWED BY ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR ADULTS WITH RELAPSED OR REFRACTORY PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Jae-Ho Yoon, 267256
A MULTICENTER, RETROSPECTIVE STUDY TO EVALUATE EFFICACY AND SAFETY OF BUSULFAN/FLUDARABINE CONDITIONING FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Seung-Shin Lee, 267257
AT1413 ANTIBODY DERIVED FROM A CURED AML PATIENT RECOGNIZES A UNIQUE CD43 EPITOPE SHARED BY AML, MDS AND MELANOMA AND HAS IN VIVO ACTIVITY AS UNMODIFIED ANTIBODY AND AS BISPECIFIC T CELL ENGAGER
EHA Learning Center, Greta de Jong, 267272
THE AML SECRETOME AND T CELL FUNCTION: MODULATION OF AMG 330-MEDIATED T CELL PROLIFERATION AND CYTOTOXICITY
EHA Learning Center, Anna Maier, 267273
ABNORMAL DNA METHYLATION MODIFIES HOX GENES EXPRESSION IN BONE MARROW MESENCHYMAL STROMAL CELLS OF MYELODYSPLASIAS AND DE NOVO ACUTE MYELOID LEUKEMIAS
EHA Learning Center, Benjamin Roux, 267290
INTEGRATED ANALYSIS OF NTAL RELATED GENES IMPROVES OUTCOMES PREDICTION OF EUROPEAN LEUKEMIANET 2008 RISK STRATIFICATION IN ACUTE MYELOID LEUKEMIA
EHA Learning Center, Diego Antonio Pereira-Martins, 267291

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings